Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Background. Over the last decades, liver resection has become a frequently performed procedure in western countries because of its acceptance as the most effective treatment for patients with selected cases of metastatic tumours. The purpose of this study was to evaluate the results after hepatic resections performed electively in our centre since 1979 and compare the results to those of larger high-volume centres. Methods. Medical records of all patients who underwent liver resection from January 1979 to December 2011 were reviewed. Disease-free survival and overall survival were ...
Background: Liver resection for colorectal liver metastases offers a 5-year survival rate of 25%–58%...
Objective: The aim of this study was to investigate variation in the frequency of resections for col...
Background: Liver resection for colorectal liver metastases offers a 5-year survival rate of 25%–58%...
Background: Liver resection is an accepted treatment modality for malignant disease of the liver. Ho...
BACKGROUND: The relationship between volume and outcome has been established in the literature for s...
Item does not contain fulltextBACKGROUND: Surgical resection of both the primary tumor and all metas...
BACKGROUND: Non-anatomical liver resections have become more common in the management of colorectal ...
The original publication is available at www.springerlink.comBackground: Hepatic resection is the tr...
Purpose : Hepatic resection for metastatic colorectal cancer has recently become a widely acceptable...
Background: The presence of extrahepatic disease, bilobar disease or greater than four hepatic lesio...
Contains fulltext : 238990.pdf (Publisher’s version ) (Closed access)BACKGROUND: B...
AbstractBackgroundHepatic resection is a potentially curative therapy for hepatocellular carcinoma (...
Objective: To examine recurrence and survival rates for patients treated with hepatic resection only...
INTRODUCTION: In a case controlled analysis, we attempted to determine if the volume-survival benefi...
Objective: The aim of this study was to investigate variation in the frequency of resections for col...
Background: Liver resection for colorectal liver metastases offers a 5-year survival rate of 25%–58%...
Objective: The aim of this study was to investigate variation in the frequency of resections for col...
Background: Liver resection for colorectal liver metastases offers a 5-year survival rate of 25%–58%...
Background: Liver resection is an accepted treatment modality for malignant disease of the liver. Ho...
BACKGROUND: The relationship between volume and outcome has been established in the literature for s...
Item does not contain fulltextBACKGROUND: Surgical resection of both the primary tumor and all metas...
BACKGROUND: Non-anatomical liver resections have become more common in the management of colorectal ...
The original publication is available at www.springerlink.comBackground: Hepatic resection is the tr...
Purpose : Hepatic resection for metastatic colorectal cancer has recently become a widely acceptable...
Background: The presence of extrahepatic disease, bilobar disease or greater than four hepatic lesio...
Contains fulltext : 238990.pdf (Publisher’s version ) (Closed access)BACKGROUND: B...
AbstractBackgroundHepatic resection is a potentially curative therapy for hepatocellular carcinoma (...
Objective: To examine recurrence and survival rates for patients treated with hepatic resection only...
INTRODUCTION: In a case controlled analysis, we attempted to determine if the volume-survival benefi...
Objective: The aim of this study was to investigate variation in the frequency of resections for col...
Background: Liver resection for colorectal liver metastases offers a 5-year survival rate of 25%–58%...
Objective: The aim of this study was to investigate variation in the frequency of resections for col...
Background: Liver resection for colorectal liver metastases offers a 5-year survival rate of 25%–58%...